TIMELESS trial shows no benefit of TNK in the extended time window of 4.5-24 hours of LKW among patients with ICA/M1/M2 occlusion did not show benefit on the 90-day mRS without any signal of safety concerns. #ESOC2023
ARCADIA shows no benefit with apixaban compared to aspirin in pts with ESUS and atrial cardiopathy. About 4% rate in both groups, no safety concerns. Where does this leave the ESUS concept? #ESOC2023
@hoomankamel @MitchElkind
More emerging data from Drs. Boe, Gaist, and colleagues supporting the heightened cardiovascular risk in ICH survivors. Enjoyed writing this invited commentary with @WCMCNeurology chief resident @ML_Simonetto@JAMANetworkOpen
https://t.co/8OedoLayOk
Hi, I promise, last push:
*Please complete* survey on smoking cessation treatments after stroke/TIA.
Stroke docs, neurohospitalists, neurologists who care for #stroke /TIA:
https://t.co/21d88g5cC8
@hoomankamel@draravindganesh@NeurologyCP@StrokeAHA_ASA
Prof. Diederik Dippel presented the results of the MR CLEAN MED trial. Clear conclusion: avoid both aspirin and heparin during EVT for acute ischemic stroke. A good example of the importance of interim analyses by a strong DSMB! @ESOstroke @Ellis_van_Etten #GSSW#MRCLEAN
Congratulations to this team led by our @merkler_alex for this important ESUS study in @JAMANeuro demonstrating rivaroxaban superiority to aspirin in recurrent #stroke or systemic embolism in left ventricular dysfunction. @hoomankamel@WeillCornell